These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26245216)

  • 1. Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.
    Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
    J Crohns Colitis; 2015 Nov; 9(11):1032-42. PubMed ID: 26245216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
    J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.
    Reilly MC; Gerlier L; Brabant Y; Brown M
    Clin Ther; 2008 Feb; 30(2):393-404. PubMed ID: 18343277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial.
    Louis E; Löfberg R; Reinisch W; Camez A; Yang M; Pollack PF; Chen N; Chao J; Mulani PM
    J Crohns Colitis; 2013 Feb; 7(1):34-43. PubMed ID: 22480772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
    Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
    Gut; 2014 Jun; 63(6):919-27. PubMed ID: 23878167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort.
    Claudepierre P; Van den Bosch F; Sarzi-Puttini P; Vastesaeger N; Govoni M; Kachroo S
    Int J Rheum Dis; 2019 Jun; 22(6):995-1001. PubMed ID: 30989813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
    Billiet T; Papamichael K; de Bruyn M; Verstockt B; Cleynen I; Princen F; Singh S; Ferrante M; Van Assche G; Vermeire S
    J Crohns Colitis; 2015 Dec; 9(12):1120-6. PubMed ID: 26351386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease.
    Buhl S; Dorn-Rasmussen M; Brynskov J; Ainsworth MA; Bendtzen K; Klausen PH; Bolstad N; Warren DJ; Steenholdt C
    Scand J Gastroenterol; 2020 Aug; 55(8):884-890. PubMed ID: 32631131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn's disease.
    Sumi R; Nakajima K; Iijima H; Wasa M; Shinzaki S; Nezu R; Inoue Y; Ito T
    Surg Today; 2016 Aug; 46(8):922-9. PubMed ID: 26438200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease.
    Davidov Y; Ungar B; Bar-Yoseph H; Carter D; Haj-Natour O; Yavzori M; Chowers Y; Eliakim R; Ben-Horin S; Kopylov U
    J Crohns Colitis; 2017 May; 11(5):549-555. PubMed ID: 28453755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of Relationship Between Crohn's Disease Activity Index or C-Reactive Protein and Infliximab Exposure Calls for Objective Crohn's Disease Activity Measures for the Evaluation of Treatment Effects at Treatment Failure.
    Edlund H; Grisic AM; Steenholdt C; Ainsworth MA; Brynskov J; Huisinga W; Kloft C
    Ther Drug Monit; 2019 Apr; 41(2):235-242. PubMed ID: 30883516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Cytokines and Cytokine Receptors in Infliximab Treatment Failure Due to TNF-α Independent Crohn Disease.
    Steenholdt C; Coskun M; Buhl S; Bendtzen K; Ainsworth MA; Brynskov J; Nielsen OH
    Medicine (Baltimore); 2016 Apr; 95(16):e3417. PubMed ID: 27100432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fecal Calprotectin Pretreatment and Induction Infliximab Levels for Prediction of Primary Nonresponse to Infliximab Therapy in Crohn's Disease.
    Beltrán B; Iborra M; Sáez-González E; Marqués-Miñana MR; Moret I; Cerrillo E; Tortosa L; Bastida G; Hinojosa J; Poveda-Andrés JL; Nos P
    Dig Dis; 2019; 37(2):108-115. PubMed ID: 30149385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Infliximab, Antidrug Antibodies, and Tumor Necrosis Factor Predict Sustained Response in Pediatric Crohn's Disease.
    Stein R; Lee D; Leonard MB; Thayu M; Denson LA; Chuang E; Herskovitz R; Kerbowski T; Baldassano RN
    Inflamm Bowel Dis; 2016 Jun; 22(6):1370-7. PubMed ID: 27057683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.
    Schnitzler F; Fidder H; Ferrante M; Noman M; Arijs I; Van Assche G; Hoffman I; Van Steen K; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):492-500. PubMed ID: 18832518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term risk of infection in patients with Crohn's disease on anti-TNF treatment: A prospective single-center cohort study in China.
    Li Y; Shu HJ; Lu H; Yang H; Li J; Tan B; Qian JM
    J Dig Dis; 2017 Jul; 18(7):388-394. PubMed ID: 28644565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy.
    Hendler SA; Cohen BL; Colombel JF; Sands BE; Mayer L; Agarwal S
    J Crohns Colitis; 2015 Mar; 9(3):266-75. PubMed ID: 25540149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Ainsworth MA
    Am J Gastroenterol; 2014 Jul; 109(7):1055-64. PubMed ID: 24796769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn's Disease.
    Ling J; Buurman D; Ravikumara M; Mews C; Thacker K; Grover Z
    Dig Dis Sci; 2018 Apr; 63(4):1003-1010. PubMed ID: 29480415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.